Just two therapies are available to treat MASH. The first was Madrigal Pharmaceuticals’ Rezdiffra (resmetirom), which was ...

Birth volume was the dominant predictor; lowest-volume rural hospitals had 36% predicted obstetric unit closure probability versus 5% in highest-volume rural hospitals, and low-volume urban hospitals ...

Steering claims away from 340B-eligible pharmacies is one option but also the most disruptive, said Jeff Dunn, Pharm.D., MBA, of NeosRx. Employers and other plan sponsors have few good options for ...

This is connected care in action: bringing together data, benefits, and personalized support to improve health outcomes while helping manage long-term healthcare costs. The value comes not from ...

Meta-analysis of 13 RCTs (2002–2024; eight countries) found VR reduced pain (SMD −0.76) and anxiety (SMD −1.53), largely ...

Employers that decide to stop covering GLP-1s for weight loss are increasingly pairing that decision with support for the ...

In stage II–IIIA disease, adjuvant osimertinib reduced mortality risk by 47%, with 74% alive at eight years versus 58% with ...

Poh says treatment of follicular lymphoma is entering an exciting era in follicular lymphoma with multiple treatment options ...

Patients with hidradenitis suppurativa show elevated levels of dozens of inflammatory proteins in their blood, and several of ...

Chad Hatfield, Pharm.D., M.H.A., BCPS, vice president and chief pharmacy officer of UC Davis Health, says pharmacists are embedded in “nearly all specialties," with more than 150 holding board ...

Divergent stakeholder needs emerged, with physicians prioritizing PA reduction and access tools, while patients prioritize affordability education, coverage clarity, and ongoing adherence support.

OrionRx's Don Anderson, Pharm.D., says a GLP-1 access model built around mandatory wellness coaching resulted in a six-point ...